Over the past five months, three state boards have told their licensees essentially the same thing about research-grade peptides, and the message is aimed squarely at prescribers rather than the companies selling the vials. Alabama publicly announced its notice in May 2026, and in mid-August the South Carolina Board of Medical Examiners and Mississippi's medical, nursing, and pharmacy boards followed within about a day of each other. If you prescribe peptides, run a longevity or weight loss program, or supervise PAs and NPs who do either, these notices are relevant to you even if your own state hasn't said a word yet.
What the boards said
South Carolina posted its notice on the prescribing of research-grade and FDA-ineligible peptides, and Mississippi's three boards issued a joint statement. Read side by side with Alabama's, the language is close enough in places that it looks like a template moving from board to board. The core points are the same across all three:
- Licensees may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved "research-grade" peptides to patients.
- Patient consent forms and waivers do not remove the provider's professional or legal responsibility.
- Delegation is not a workaround. South Carolina extended the prohibition to delegating to APRNs and PAs, and Mississippi said a provider cannot get around the duty of care by having other providers handle purchasing, administration, or dispensing.
- Drugs and ingredients have to come from entities permitted by the state board of pharmacy, and Mississippi invited reports of unlicensed companies shipping into the state.
- South Carolina also called out facilities marketing semaglutide salt forms and research-grade powders, and said only prescription-quality material should be used in compounding.
Why this lands on prescribers
Most of the peptide enforcement we've seen so far has gone after the supply side, including FDA warning letters to research-use sellers, manufacturer lawsuits, and pharmacy board actions. Ohio's Board of Pharmacy, for example, has issued summary suspension orders and settlements against clinics and distributors where peptides like AOD-9604, BPC-157, and ipamorelin turned up, and Nevada's pharmacy board issued citations after two women were hospitalized and intubated following injections of experimental peptides and vitamins at an anti-aging conference in Las Vegas.
The medical board notices move the focus to the license itself, which is a different kind of exposure. A board doesn't need a new peptide statute to act, because nearly every state's practice act already has a standard of care or unprofessional conduct provision that covers this. Board discipline is also reported nationally and tends to follow a clinician into every other state where they hold a license, which is why it matters so much for anyone practicing across state lines.
This is the same pattern Camino has highlighted in telehealth enforcement more broadly. When there isn't a law written specifically for something, regulators lean on the authority they already have, and these notices are a good example of boards restating existing rules out loud so no one can later say they didn't know.
The PCAC vote didn't change any of this
A lot of clinics took the July 2026 Pharmacy Compounding Advisory Committee vote as a green light, and it wasn't one. The committee voted in favor of adding six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax) to the 503A bulks list, but the vote was advisory and did not amend the list, and FDA would still have to issue a proposed rule before anything formally changes. Additional peptides, including GHK-Cu and Melanotan II, are expected to receive further advisory review in early 2027; check FDA's current meeting announcements for the final schedule.
The newest development is an administration proposal that could temporarily allow certain unapproved peptides to be dispensed through compounding pharmacies while the regulations are written, and FDA's own staff are raising concerns about it. Even if something like that moves forward, it would cover compounding from licensed pharmacies using eligible ingredients. It would not cover a research-use-only vial bought from a website, which is exactly what these board notices are about. The issue is the sourcing and the verification, not the molecule.
Camino's view hasn't changed since the vote: these rollouts are not quick, because FDA has to write the policy and build the monitoring and audit side before anything is actually different on the ground. In the meantime, the state boards are filling the gap.
The consent form problem
We still see a lot of "research use only, patient acknowledges" consent forms in the wild, and all three boards addressed them directly. Informed consent is how you explain the risks of a treatment that is already within the standard of care. It doesn't give a patient the ability to waive the standard itself, so a form that says the product isn't approved for human use doesn't protect the prescriber and mostly shows that the prescriber knew.
The delegation problem
This is the part we would flag for physicians supervising or collaborating with PAs and NPs. A common setup in longevity and wellness programs is a physician medical director who signs off on a peptide protocol while PAs or NPs do the actual prescribing under standing orders. South Carolina specifically closed that door, and Mississippi's language gets to the same place. If the product shouldn't be prescribed, it shouldn't be prescribed by anyone on the team, and both the supervising physician and the PA or NP are exposed.
It's also worth pulling out your malpractice policy. Many policies exclude experimental or non-FDA-approved treatments, and finding that out after a claim is a very different situation than finding it out now.
Where the states stand
There's no single national answer on peptides right now. State approaches vary, and a state's apparent silence or comparatively permissive posture is not permission to prescribe research-use-only products. State attorneys general have also raised safety concerns with FDA about unapproved and counterfeit weight-loss products. For a telehealth company, the patient's location is a key jurisdictional consideration; review the applicable requirements in every state served rather than treating one state's rules as national authorization. We expect more boards to issue similar notices, and because the language is already written, it is easy for the next state to adopt.
What to do now
- List every peptide on your formulary and where it comes from, and confirm the pharmacy holds a current permit in each patient's state.
- Confirm the ingredient itself is eligible for compounding and comes with a certificate of analysis, not just that the pharmacy is licensed.
- Remove any research-use-only product from the clinical side entirely, and keep any separate research-use business truly separate in branding, customers, and operations.
- Retire research-grade waivers and have counsel review your consent documents.
- Review protocols and standing orders for anything delegated to PAs or NPs.
- For GLP-1 programs, confirm your pharmacy is not using semaglutide salt forms.
- Review your website, social content, and intake funnel for peptide claims, since that is usually the first thing an investigator reads.
- Check your malpractice policy for exclusions on non-FDA-approved treatments.
How Camino helps
Camino works with longevity, weight loss, and telehealth programs on the operational side of this: formulary and protocol review, pharmacy vendor diligence across every state you serve, medical director and collaboration structures that hold up, and intake and consent workflows that match how care is actually delivered. If you're prescribing peptides or supervising a team that does and want to see where your program stands, reach out and we'll walk you through it.
References
Board notices and linked analyses should be checked for updates. Additional reading supplied with this article is listed by publication and title below.
- Alabama Board of Medical Examiners: Official notice on research-grade peptides
- Mississippi medical, nursing, and pharmacy boards: Joint peptide statement (PDF)
- South Carolina Board of Medical Examiners
- LumaLex Law: What Mississippi and South Carolina Just Said About Research-Grade Peptides
- Partnership for Safe Medicines, September 16, 2026
- Partnership for Safe Medicines, October 13, 2026
- Buchanan Ingersoll & Rooney: FDA Voted Yes on Six Peptides, Now What?
- Orrick: FDA Peptide Compounding Vote
- Frier Levitt: Proposed peptide enforcement discretion policy
- AJMC: Peptide Regulation Debate Intensifies
- MM+M: People say these peptides hurt them
Related reading: Temporary peptide policy developments · Retatrutide enforcement
This post is for general information only and is not legal advice. For guidance on your specific situation, talk with qualified healthcare counsel.